Shares of Merck & Co. Inc. MRK dropped 0.58% to $114.96 Tuesday, on what proved to be an all-around positive trading session ...

Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...

PWHL names and logos are out and the debate around who hit the mark and who missed is already raging on social media. In reality, there is nothing to say any of the PWHL's six logos is veritably bad.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

It is going to look a little bizarre, but there is a great reason behind the change… Nike have changed their logo on third kits to celebrate women's football. They explained their switch for ...

Top choices will include extras like the best free stock image websites and vector graphics libraries. These are essential for producing logos like no other. We want to see simple-to-use platforms ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Reddit thread started Thursday titled, "What's wrong with the Facebook logo?" shows a blue lowercase "f" on a black background instead of a blue background with a white "f." Some users who have ...

Aug 29 (Reuters) - Merck (MRK.N), opens new tab has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

(Reuters) - Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...